Rapid Micro Biosystems, Inc. Q4 2025 Earnings Call Summary

Achieved record fourth quarter revenue of $11.3 million, representing 37% year-over-year growth and the 13th consecutive quarter of meeting or exceeding expectations. Performance was driven by a record 16 system placements in Q4, including a major global rollout with Amgen across North America, Europe, and Asia. Samsung Biologics is expanding its Growth Direct deployment with a new multisystem order in Q1 2026, validating the platform's role in next-generation manufacturing. Consumable revenue grew ...